Feng Chi Biotech Corp. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 104.16 million compared to TWD 99.68 million a year ago.

Net income was TWD 13.81 million compared to TWD 15.65 million a year ago. Basic earnings per share from continuing operations was TWD 0.9 compared to TWD 1.02 a year ago. Diluted earnings per share from continuing operations was TWD 0.89 compared to TWD 1.02 a year ago.